1 EXECUTIVE SUMMARY
1.1 OVERVIEW 11
1.1.1 MARKET SYNOPSIS 11
2 MARKET INTRODUCTION
2.1 DEFINITION 12
2.2 SCOPE OF THE STUDY 12
2.3 RESEARCH OBJECTIVE 12
2.4 LIST OF ASSUMPTIONS & LIMITATIONS 13
3 RESEARCH METHODOLOGY
3.1 DATA MINING 14
3.2 SECONDARY RESEARCH 15
3.3 PRIMARY RESEARCH 16
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 16
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 17
3.4 FORECASTING TECHNIQUES 18
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 19
3.5.1 BOTTOM-UP APPROACH 20
3.5.2 TOP-DOWN APPROACH 20
3.6 DATA TRIANGULATION 21
3.7 VALIDATION 21
4 MARKET DYNAMICS
4.1 OVERVIEW 22
4.2 DRIVERS 23
4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 23
4.2.2 TECHNOLOGICAL ADVANCEMENTS IN THE TREATMENT THERAPIES FOR CANCER 23
4.2.3 GROWING PHARMACEUTICAL INDUSTRY 23
4.2.4 INCREASE IN THE NUMBER OF CLINICAL STUDIES FOR CELL THERAPY 24
4.3 RESTRAINTS 25
4.3.1 SIDE EFFECTS OF CAR T-CELL THERAPY 25
4.3.2 HIGH COST OF TREATMENT 25
4.4 OPPORTUNITY 26
4.4.1 INVESTIGATION ON CAR-T THERAPY FOR THE TREATMENT OF SEVERAL HEMATOLOGIC AND SOLID
TUMOR TYPES 26
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES ANALYSIS 27
5.1.1 THREAT OF NEW ENTRANTS 27
5.1.2 BARGAINING POWER OF SUPPLIERS 28
5.1.3 BARGAINING POWER OF BUYERS 28
5.1.4 THREAT OF SUBSTITUTES 28
5.1.5 INTENSITY OF RIVALRY 28
5.2 CLINICAL TRIALS ANALYSIS 29
5.3 COVID-19 IMPACT ANALYSIS 36
5.3.1 IMPACT ON GDP GROWTH 36
5.3.2 IMPACT ON SUPPLY CHAIN 37
5.3.3 IMPACT ON PRODUCTION 37
5.3.4 IMPACT ON KEY PLAYERS 37
6 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN
6.1 OVERVIEW 38
6.1.1 CD19 39
6.1.2 CD22 40
6.1.3 OTHERS 40
7 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION
7.1 OVERVIEW 41
7.1.1 DIFFUSE LARGE B-CELL LYMPHOMA 43
7.1.2 ACUTE LYMPHOBLASTIC LEUKEMIA 44
7.1.3 OTHERS 44
8 GLOBAL CAR T CELL THERAPY MARKET, BY REGION
8.1 OVERVIEW 45
8.2 US 46
8.3 EUROPE 48
8.4 CHINA 49
8.5 REST OF THE WORLD (ROW) 50
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW 51
9.2 MAJOR PLAYERS IN THE GLOBAL CAR T CELL THERAPY MARKET 51
9.3 COMPETITIVE BENCHMARKING 52
9.4 COMPETITOR DASHBOARD 53
9.5 DEVELOPMENTS IN THE GLOBAL CAR TCELL THERAPY MARKET 53
9.5.1 ACQUISITION 53
9.5.2 JOINT VENTURES 54
9.5.3 EXPANSION 55
9.5.4 REGULATORY APPROVALS 56
9.5.5 IND CLEARANCES 56
9.5.6 PRODUCT LAUNCH/PRODUCT APPROVAL 57
10 COMPANY PROFILES
10.1 NOVARTIS AG 58
10.1.1 COMPANY OVERVIEW 58
10.1.2 FINANCIAL OVERVIEW 58
10.1.3 PRODUCTS/SERVICES OFFERED 59
10.1.4 KEY DEVELOPMENTS 59
10.1.5 SWOT ANALYSIS 60
10.1.6 KEY STRATEGIES 60
10.2 PFIZER, INC. 61
10.2.1 COMPANY OVERVIEW 61
10.2.2 FINANCIAL OVERVIEW 61
10.2.3 PRODUCTS/SERVICES OFFERED 62
10.2.4 KEY DEVELOPMENTS 62
10.2.5 SWOT ANALYSIS 63
10.2.6 KEY STRATEGIES 63
10.3 KITE PHARMA 64
10.3.1 COMPANY OVERVIEW 64
10.3.2 FINANCIAL OVERVIEW 64
10.3.3 PRODUCTS/SERVICES OFFERED 65
10.3.4 KEY DEVELOPMENTS 65
10.3.5 SWOT ANALYSIS 66
10.3.6 KEY STRATEGIES 66
10.4 CELLECTIS 67
10.4.1 COMPANY OVERVIEW 67
10.4.2 FINANCIAL OVERVIEW 67
10.4.3 PRODUCTS/SERVICES OFFERED 68
10.4.4 KEY DEVELOPMENTS 68
10.4.5 SWOT ANALYSIS 69
10.4.6 KEY STRATEGIES 69
10.5 AUTOLUS THERAPEUTICS PLC 70
10.5.1 COMPANY OVERVIEW 70
10.5.2 FINANCIAL OVERVIEW 70
10.5.3 PRODUCTS/SERVICES OFFERED 70
10.5.4 KEY DEVELOPMENTS 71
10.5.5 SWOT ANALYSIS 71
10.5.6 KEY STRATEGIES 71
10.6 CARSGEN THERAPEUTICS 72
10.6.1 COMPANY OVERVIEW 72
10.6.2 FINANCIAL OVERVIEW 72
10.6.3 PRODUCTS/SERVICES OFFERED 72
10.6.4 KEY DEVELOPMENTS 72
10.6.5 SWOT ANALYSIS 73
10.6.6 KEY STRATEGIES 73
10.7 JUNO THERAPEUTICS 74
10.7.1 COMPANY OVERVIEW 74
10.7.2 FINANCIAL OVERVIEW 74
10.7.3 PRODUCTS/SERVICES OFFERED 75
10.7.4 KEY DEVELOPMENTS 75
10.7.5 SWOT ANALYSIS 75
10.7.6 KEY STRATEGIES 76
10.8 SORRENTO THERAPEUTICS, INC. 77
10.8.1 COMPANY OVERVIEW 77
10.8.2 FINANCIAL OVERVIEW 77
10.8.3 PRODUCTS OFFERING 77
10.8.4 KEY DEVELOPMENTS 78
10.8.5 SWOT ANALYSIS 78
10.8.6 KEY STRATEGY 78
10.9 LEGEND BIOTECH 79
10.9.1 COMPANY OVERVIEW 79
10.9.2 FINANCIAL OVERVIEW 79
10.9.3 PRODUCTS/SERVICES OFFERED 80
10.9.4 KEY DEVELOPMENTS 80
10.9.5 SWOT ANALYSIS 81
10.9.6 KEY STRATEGIES 81
10.10 MUSTANG BIO 82
10.10.1 COMPANY OVERVIEW 82
10.10.2 FINANCIAL OVERVIEW 82
10.10.3 PRODUCTS/SERVICES OFFERED 83
10.10.4 KEY DEVELOPMENTS 83
10.10.5 SWOT ANALYSIS 84
10.10.6 KEY STRATEGIES 84
11 APPENDIX
11.1 REFERENCES 85
11.2 RELATED REPORTS 85
12 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 13
TABLE 2 CLINICAL TRIALS OVERVIEW 29
TABLE 3 KEY COMPANIES AND NUMBER OF CLINICAL TRIALS 36
TABLE 4 GLOBAL CAR T CELL THERAPY MARKET BY TARGET ANTIGEN, 2020-2027 (USD MILLION) 39
TABLE 5 GLOBAL CAR T CELL THERAPY MARKET FOR CD19, BY REGION, 2020-2027 (USD MILLION) 39
TABLE 6 GLOBAL CAR T CELL THERAPY MARKET FOR CD22, BY REGION, 2020-2027 (USD MILLION) 40
TABLE 7 GLOBAL CAR T CELL THERAPY MARKET BY APPLICATION, 2020-2027 (USD MILLION) 42
TABLE 8 GLOBAL CAR T CELL THERAPY MARKET FOR DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2020-2027 (USD MILLION) 43
TABLE 9 GLOBAL CAR T CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2020-2027 (USD MILLION) 44
TABLE 10 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION) 46
TABLE 11 US CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2020-2027 (USD MILLION) 46
TABLE 12 US CAR T CELL THERAPY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 47
TABLE 13 EUROPE CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2020-2027 (USD MILLION) 48
TABLE 14 EUROPE CAR T CELL THERAPY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 48
TABLE 15 CHINA CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2020-2027 (USD MILLION) 49
TABLE 16 CHINA CAR T CELL THERAPY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 49
TABLE 17 REST OF THE WORLD (ROW) CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2020-2027 (USD MILLION) 50
TABLE 18 REST OF THE WORLD (ROW) CAR T CELL THERAPY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 50
TABLE 19 MAJOR PLAYERS IN THE GLOBAL CAR T CELL THERAPY MARKET 51
TABLE 20 COMPETITOR DASHBOARD: GLOBAL CAR T SCELL THERAPY MARKET 53
TABLE 21 ACQUISITION 53
TABLE 22 JOINT VENTURES 54
TABLE 23 EXPANSION 55
TABLE 24 REGULATORY APPROVALS 56
TABLE 25 IND CLEARANCES 56
TABLE 26 PRODUCT LAUNCH/PRODUCT APPROVAL 57
13 LIST OF FIGURES
FIGURE 1 GLOBAL CAR T CELL THERAPY MARKET STRUCTURE 13
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 19
FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CAR T-CELL THERAPY MARKET 22
FIGURE 4 DRIVERS: IMPACT ANALYSIS 24
FIGURE 5 RESTRAINTS: IMPACT ANALYSIS 25
FIGURE 6 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL CAR T CELL THERAPY MARKET 27
FIGURE 7 ONGOING CLINICAL TRIAL PHASES (%) 35
FIGURE 8 KEY COMPANIES’ CLINICAL TRIALS, (%) 36
FIGURE 9 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2020 (%) 38
FIGURE 10 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2020 & 2027 (USD MILLION) 38
FIGURE 11 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION, 2020 (%) 41
FIGURE 12 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION, 2020 & 2027 42
FIGURE 13 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2020 (%) 45
FIGURE 14 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 45
FIGURE 15 BENCHMARKING OF MAJOR COMPETITORS 52
CAR T Cell Therapy Market
CAR-T cell therapy market will grow at CAGR of 48.96% to hit USD 10,415.61 million by 2027
$10,415.61 million
Market Size
48.96%
CAGR
North America
Dominating Region
2020-2027
Forecast Period
Segmentation
Key Players
- Bluebird Bio (US)
- Intellia Therapeutics (US)
- Noile-Immune Biotech (Japan)
- Celgene Corporation (US)
- Bellicum Pharmaceuticals
- Inc. (US)
- Novartis International AG (Swiss)
- Celyad (Belgium)
- Cellectis (France)
- Servier Laboratories (France)
- Pfizer Inc. (US)
Drivers
- prevalence of cancers is increasing the demand for effective treatment
- The growth of the obese population
CAR-T Cell Therapy Market Overview
The rising market trends and demand are likely to show a positive result for the CAR-T cell therapy market size. Based on the forecast laid by the industry experts, the market is likely to grow at a CAGR of 48.96% during the forecast period and reach a final market value worth USD 10,415.61 million by the end of the period in 2027. Chimeric Antigen Receptor (CAR)-T is a novel treatment that includes reengineering of the WBC’s of the patient to help in fighting the malignant cells by identifying them.
COVID 19 Analysis of CAR-T Cell Therapy Market
Owing to the advanced degree to which the global coronavirus pandemic is unfolding and the continuous variants and waves that have disrupted the lives of people across the globe, the industries, and market players are equally suffering the wrath. So much so, that some of the business players have given up and they are shutting their manufacturing and production units. Also, the imposed lockdown has not proved to be of any benefit as people are working from home which is disrupting both their personal and professional life, thus, resulting in an increased degree of unavailability of a skilled workforce that is further, hampering the ability to meet the demand quantum as a result of inefficient production. Also, the raw material available is no or very little quantity that is hampering the quality of products and it has become nearly impossible for the businesses to function amid a series of restrictions and cross-border difficulties.
Hence, the need of the hour is for the public sector to intervene and the governments of the global locations to enhance the funds that will help in the market’s revival. Also, it is important to understand that the population is increasing and the demands of people are different. The key market players should enhance their production ability and take it to the international market to launch a variety of products. Also, mergers and acquisitions are an important and innovative way to help the target audience choose from a variety of products and change their lifestyle preferences accordingly.
CAR-T Cell Therapy Market Dynamics
Drivers
The CAR-T cell therapy market companies are expected to thrive at an excellent rate during the ongoing forecast period of 2021-2028. The overall industry has a very dynamic approach and the key players belonging to the market are gaining access in the major CAR-T cell therapy market size. The companies are securing the treatment centers that will help in increasing patients owing to the development of a series of medical service demands.
Restraints
There have various growth restraints that emerge as major issues for the market while on its path of growth during the forecast period that ends in 2028. One of the major restraints that the market players tend to face is the lack of demand for treatment. The target population is too rigid and understands the native methods of treatment only. Also, the associated cost for treatment is very high that does not sit well with the people as they belong to different income groups and spending capacities. If the cost and prices are not reduced, the global CAR-T cell therapy market trends and operations are likely to pose major restraints for the market and bar the market from growing as per the predictions laid by the industry leaders and CAR-T cell therapy market experts during the forecast period of 2021-2028.
Technology Analysis
The rising rate of people being diagnosed with various types of cancer is one of the major reasons that lead to the death of the global population. Hence, the need of the hour is for the companies to evolve the conventional and cytotoxic immunotherapies that are available on the global market scale. The tumors are believed to have complex behaviors and the degree of involvement of a variety of cellular and genetic factors in metastasis and tumorigenesis is pushing the companies to divert their trends in the development of new treatment trends so that the main focus lays on tumors at both the stated levels.
Study Objectives
- To understand the growth scope of the market during the ongoing forecast period that ends in 2028 considering the dynamics in the form of drivers and restraints that will impact the CAR-T cell therapy market figures in form of the CAGR growth rate followed by the attainable market revenue by the ongoing forecast period after the pandemic year of 2020.
- To analyze the scope of the CAR-T cell therapy market growth based on the bifurcation of the market in the form of segments that are spread in various global regions and catering to the need of the target audience in these regions during the period ending in 2028.
- To study the attainable growth rate of the CAR-T cell therapy market based on the recent developments undertaken by the market players during the period and subsequently, draw a competitive graph amongst these players that are active in maintaining the supply chain mechanism of the global CAR-T cell therapy market.
CAR-T Cell Therapy Market Segment Overview
The CAR-T cell therapy market report shows that the market has been segmented based on the following:
Based on the Target antigen:
The global CAR-T cell therapy market by targeted antigen includes BCMA that is B-Cell maturation antigen, CD19/CD22, and others like PSCA, Lewis Y, ROR1, NKR-2, and MUC16 amongst others.
Based on the Application:
The indication segment of the CAR-T cell therapy market includes Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia and Other.
Based on Geography:
Based on the division of the target audience, types of equipment, and resources, the CAR-T cell therapy market has been divided into 4 major regions namely North America, Europe, the APAC region, and the rest of the world.
CAR-T Cell Therapy Market Regional Analysis
The CAR-T cell gene therapy market analysis shows that the North American region shows signs of excellent growth during the period and is expected to grow at a global CAGR of 36.4%. Similarly, the changing trends in the European market and the increased use of proper technology will help the CAR-T cell therapy market grow at a significant rate. The recommended approvals of Yescarta and Kymriah by the European Medicine Agencies (EMA), are showing signs of positive attributes that will help the market boost its overall growth during the forecast period that ends in 2028.
Competitive Landscape
The rising degree of competition in the global CAR-T cell therapy market scenario is the result of recent developments of CAR-T cell therapy companies. They are as follows:
- Bluebird Bio (US)
- Intellia Therapeutics (US)
- Noile-Immune Biotech (Japan)
- Celgene Corporation (US)
- Bellicum Pharmaceuticals, Inc. (US)
- Novartis International AG (Swiss)
- Celyad (Belgium)
- Cellectis (France)
- Servier Laboratories (France)
- Pfizer Inc. (US)
- Caribou Biosciences, Inc. (US)
- Mereck KGaA (Germany)
- Amgen Inc. (US)
Recent Developments
- The pharmaceutical and biotech companies are opening their doors towards mergers and acquisitions alongside showing their willingness to enter into partnerships. One of the main aims behind this intention is to win a competitive edge over the competitors in the international market scale. For instance, Celgene Corporation came forward and acquired Juno Therapeutics Inc. for a CAR-T cell therapy market value of USD 9 billion during 2018.
- The multiple CAR-T cell therapy market is expecting to grow at an excellent rate and thus, attain a market value worth USD 2.1 billion by the end of 2026. The first approved therapy was in the field of pediatrics and young adults acute lymphoblastic leukemia (ALL). This is an ailment that has a huge unmet need. The CAR-T helps in indicating higher effectiveness having its representation in a small population chunk.
- In February 2018, another prominent market player Gilead Sciences Inc. entered into a partnership with Sangamo Therapeutics Inc. The main idea behind this is for the gene-editing technology that is a major development for the treatment of diseases like cancer. The estimated market value for this partnership deal stands at USD 3 billion and is likely to help the involved parties enhance their global presence during the forecast period that ends in 2028.
Report Overview
The curated reports aim to have a deep and helpful discussion of the global manufacturing of the CAR-T cell therapy in terms of the market trends and dynamics that will lead the market towards splendid growth during the ongoing forecast period that ends in 2028. The CAR-T cell therapy market report aims to help the market investors gain qualitative market insights related to the performance of the market segments and the growth strategies taken by the market players in various regions during the period that will help both the companies and the domestic regions to grow on the international market scale. Also, the report is a clear depiction of the rising competition amongst the key market players and the aim is to consider the recent developments undertaken during the ongoing forecast period that ends in 2028.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | USD 10,415.61 Million |
| CAGR | 42.98% |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Target Antigen, Application and Region |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Pfizer (US), Kite Pharma (US), Novartis (Switzerland), Cellectis (Switzerland) and Juno Therapeutics (US) |
| Key Market Opportunities | Increase in the setups of research & development centers and the inclination of top companies toward the developing countries boost |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The Market is expected to rise to a valuation of USD 10,415.61 Million by 2027.
The global market is expected to exhibit a strong 42.98% CAGR over the forecast period from 2019 to 2025.
The growing prevalence of cancer and the growing support for the development of effective therapies against cancer is the major driver for the market.
The U.S. holds an overwhelming majority in the global market and is likely to remain the dominant regional market over the forecast period.
Leading players in the market include Novartis, Pfizer, Juno Therapeutics, Kite Pharma, Autolus Therapeutics plc, CARsgen Therapeutics, Cellectis, and Sorrento Therapeutics, among others.
